Liminatus Pharma, Inc. Class A

Stage 4 · Declining · week 35

As of Oct 22, 2026, Liminatus Pharma is in Stage 4, the downtrend phase, now in week 35 (since Feb 18, 2026). It closed at $3.11, 97.0% below its 52-week high and below its 200-day average, which is falling.

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. More about the company

$3.11

-0.32% today

$4.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is LIMN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-05-02 → 2026-10-22

S? 42w

S4 35w

2025-05-022026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 35w current

Total tracked: 77 weeks across 2 stage runs.

LIMN among Biotechnology533rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…533	LIMNLiminatus Pharma, Inc. Class A	Stage 4 · wk 35	5	−22.8%

vs 52W High

-97.0%

$3.04 lo$102.50 hi

97.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 35

1w13w26w

Week 35, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-74.5%

200 DMA: $12.20 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.05x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-22.8%

-44.0%

-68.9%

YTD

-90.3%

-94.8%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 35 · Vol 0.05x

2026-10-21S4

Wk 35 · Vol 0.45x

2026-10-20S4

Wk 34 · Vol 0.12x

2026-10-19S4

Wk 34 · Vol 0.12x

2026-10-16S4

Wk 34 · Vol 0.06x

2026-10-15S4

Wk 34 · Vol 0.06x

2026-10-14S4

Wk 34 · Vol 0.07x

2026-10-13S4

Wk 33 · Vol 0.05x

2026-10-12S4

Wk 33 · Vol 0.10x

2026-10-09S4

Wk 33 · Vol 0.06x

2026-10-08S4

Wk 33 · Vol 0.14x

2026-10-07S4

Wk 33 · Vol 0.08x

Moving averages & range

50 DMA

$4.09

200 DMA

$12.20

52W High

$102.50

52W Low

$3.04

5D Low

$3.04

Resistance levels (recent highs)

20d High

$4.27

60d High

$7.50

120d High

$12.30

250d High

$102.50

Next resistance

+37.3%

to 20d High

Dividend Yield

0.00%

P/B 11.6

Liminatus Pharma: quick answers

What stage is Liminatus Pharma in?

As of Oct 22, 2026, Liminatus Pharma (LIMN) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 18, 2026 and is in week 35. What the four stages mean

Is Liminatus Pharma in an uptrend?

No. Liminatus Pharma is in a Stage 4 downtrend. It trades 74.5% below its 200-day average, which is falling.

How far is Liminatus Pharma from its 52-week high?

Liminatus Pharma closed at $3.11 on Oct 22, 2026, 97.0% below its 52-week high of $102.50. Its 52-week low is $3.04.

How has Liminatus Pharma performed over the past year?

As of Oct 22, 2026, Liminatus Pharma is down 94.8% over the past year and down 90.3% so far in 2026.

Which sector and industry is Liminatus Pharma in?

Liminatus Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.